VILLA GUARDIA (COMO), Italy, Oct. 4, 2012 (GLOBE NEWSWIRE) -- Gentium S.p.A. (Nasdaq:GENT) announced today the appointment of Biologix FZCo as the exclusive distributor of Defibrotide in the Middle East and North Africa (MENA).
Under the terms of the agreement, which is valid for 10 years, Biologix will be responsible for managing named-patient requests and obtaining price and reimbursement approvals in the MENA region. Following regulatory approval to market Defibrotide, if any, Biologix will be responsible for sales, marketing and local medical affairs activities in this region.
"We are pleased to have established a long-term relationship with Biologix for the distribution of Defibrotide in the Middle East and North Africa, consistent with our overall commercial strategy to partner with strong local distributors," said Adrian Haigh, Senior Vice President of Commercial Operations at Gentium. "Local distribution partners with strong experience in hematology and well-established local relationships, such as Biologix, help to facilitate access to Defibrotide.""We look forward to working with Gentium and are pleased with the addition of Defibrotide to our specialty distribution portfolio. The partnership with Gentium will allow us to provide MENA patients access to this potentially life-saving treatment," said Selim Ghorayeb, Managing Partner at Biologix. About Gentium Gentium S.p.A., located in Como, Italy, is a biopharmaceutical company focused on the development and manufacture of drugs to treat and prevent a variety of diseases and conditions, including vascular diseases related to cancer and cancer treatments. Defibrotide, the Company's lead product candidate, is an investigational drug that has been granted Orphan Drug status by the U.S. Food and Drug Administration (FDA) and Orphan Medicinal Product Designation by the European Medicines Agency both to treat and to prevent veno-occlusive disease (VOD) and Fast Track Designation by the U.S. FDA to treat VOD. The Gentium S.p.A. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=12669 About Biologix Biologix FZCo, a company established under the laws of UAE in 2003, provides for the distribution and marketing of biotech products in the MENA region. Equipped with a logistics hub based in Dubai Airport Free Zone and supported by a qualified workforce, it offers effective Regulatory, Medical, Marketing, Sales and Distribution support to its partners with a direct and adequate presence in 17 countries of the Middle East and North Africa including Saudi Arabia, UAE, Kuwait, Bahrain, Oman, Qatar, Yemen, Iran, Iraq, Lebanon, Syria, Jordan, Egypt, Libya, Tunisia, Algeria, and Morocco. Biologix' main therapeutic focuses are Oncology-Hematology, Central Nervous System and Rare Diseases.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts